Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza Blazes PARP Trail In China

Executive Summary

AstraZeneca/Merck & Co’s Lynparza has become the first PARP inhibitor to be approved in China, continuing a recent trend of accelerated reviews and approvals for novel therapies from multinationals in the country.

You may also be interested in...



China Vs. Cancer: Seven Companies Given Price Cuts, Roche Gets New Approval

Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.

China Calling: Dozens Of Drug Firms Handpicked For Fast Track Reviews

Four dozen innovative new drugs are slated to be reviewed under China's fast-track system, including more than 20 products for rare diseases.

Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party

China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel